PharmiWeb.com - Global Pharma News & Resources
16-Jul-2019

Inflammatory Bowel Disease Treatment Market Will Grow at 4.1% to a Record $ 21.3 Bn by 2026

The Global Inflammatory Bowel Disease Treatment Market Size projected to register USD 21.3 billion by 2026, registering at a CAGR growth of 4.1% over the forecast period 2019 to 2026.

In the US, almost 3.1 million individuals (which is about 1.3 percent of the total country population) were either diagnosed with ulcerative colitis or Crohn's disease, according to the Center for Disease Control and Promotion (CDC). It is also estimated that almost 70,000 fresh of IBD are recorded annually in the United States. In response, the hospitalization rate has risen in America, generating opportunities in the market for the therapy of inflammatory bowel diseases. Besides this, the recent product approvals by the European Medicines Agency and other similar organizations have enabled the market gain significant momentum.

Europe was by region in 2017 the second largest market for therapy for inflammatory bowel diseases. Due to growing prevalence of inflammatory bowel disease, increased alcoholic abuse rates, unhealthy lifestyle practices and an increased incidence of anxiety and depression among adolescents, the European market is anticipated to continue to grow over the predicted era. Additionally, the growth of the inflammatory bowel disease industry in Europe is expected to propel factors such as increased public efforts and research financing, the developing of sophisticated medical therapy alternatives, and favourable reimbursement policies.

Download Free Sample Report Pages at https://www.acumenresearchandconsulting.com/request-sample/1505

The Asia Pacific market with a growing exponential increase in patient population is projected to be the fastest growing inflammatory bowel diseases therapy industry. China and Japan are forecast to be the biggest markets in Asia-Pacific for the therapy of inflammatory bowel diseases. A growing patient pool, fueling the demand for medicines, is anticipated due to the increased incidence of anxiety and depression in adolescents, together with the increased abuse of alcohol and sedentary life styles. The projected period is also anticipated to promote market growth in the relative tightness of drug regulatory policies and increased public health reform projects. The development in the Asia-Pacific inflammatory bowel diseases industry also drives higher healthcare and higher living standards in the region. In Middle East / Africa, the market is anticipated to demonstrate less development because of an absence of disease consciousness, restricted access to and access to therapy centres and reduced disease prevalence. In the UAE, Kuwait and Saudi Arabia, however, the market may expand.

Key Players amp; Strategies

Some of the vital companies in this market are Pfizer Inc.; Johnson amp; Johnson Services Inc.; AbbVie Inc; CELGENE CORPORATION; Takeda Pharmaceutical Company Limited; Innovate Biopharmaceuticals; Celltrion Healthcare Co., Ltd.; COSMO PHARMACEUTICALS; and Gilead Sciences. They are concentrated mainly on regional expansion, strategic arrangements and new product research and development.

For example, Janssen Biotech Inc. signed a strategic agreement with Protagonist Therapeutics, Inc. in 2017 to develop the oral IL 23 receiver PTG-200 for the treatment of inflammatory bowel diseases, manufactured and marketed. The European Union authorized Pfizer Inc., in 2018, to treat mild to serious ulcerative colitis by XELJANZ for marketing.

The global market for inflammatory bowel diseases, driven by product development and approvals, the increasing incidence of international IBD and the introduction of new drugs, will most probably continue to grow steadily for the next few years. On the other hand, the high availability of biological copies of popular drugs can hinder established players on the market. For example, some studies in 2017 showed that biologically similar copies of AbbVie's Humira speed up the market. The Johnson amp; Johnson's Remicade version is similarly accessible on the market already.

View Detail Information at https://www.acumenresearchandconsulting.com/inflammatory-bowel-disease-treatment-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Inflammatory Bowel Disease Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Inflammatory Bowel Disease Treatment Market By Type
1.2.2.1. Global Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Inflammatory Bowel Disease Treatment Market Revenue Share By Type in 2017
1.2.2.3. Ulcerative colitis
1.2.2.4. Crohnrsquo;s sickness
1.2.3. Inflammatory Bowel Disease Treatment Market By Route of Administration
1.2.3.1. Global Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.3.2. Oral
1.2.3.2.1. JAK inhibitors
1.2.3.2.2. ASAs
1.2.3.2.3. Corticosteroids
1.2.3.2.4. Others
1.2.3.3. Injectables
1.2.3.3.1. IL inhibitors
1.2.3.3.2. TNF-inhibitors
1.2.3.3.3. Anti-integrin
1.2.3.3.4. Others
1.2.4. Inflammatory Bowel Disease Treatment Market By Distribution Channel
1.2.4.1. Global Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.4.2. Online
1.2.4.3. Hospital
1.2.4.4. Retail
1.2.5. Inflammatory Bowel Disease Treatment Market by Geography
1.2.5.1. Global Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Inflammatory Bowel Disease Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Inflammatory Bowel Disease Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Type of Global Inflammatory Bowel Disease Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Inflammatory Bowel Disease Treatment Major Manufacturers in 2017

CHAPTER 4. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY TYPE

4.1. Global Inflammatory Bowel Disease Treatment Revenue By Type
4.2. Ulcerative colitis
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Crohnrsquo;s sickness
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

5.1. Global Inflammatory Bowel Disease Treatment Revenue By Route of Administration
5.2. Oral
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.2.3. JAK inhibitors
5.2.4. ASAs
5.2.5. Corticosteroids
5.2.6. Others
5.3. Injectables
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3.3. IL inhibitors
5.3.4. TNF-inhibitors
5.3.5. Anti-integrin
5.3.6. Others

CHAPTER 6. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

6.1. Global Inflammatory Bowel Disease Treatment Revenue By Distribution Channel
6.2. Online
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Hospital
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Retail
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY COUNTRY

7.1. North America Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Inflammatory Bowel Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Inflammatory Bowel Disease Treatment Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY COUNTRY

8.1. Europe Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Inflammatory Bowel Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY COUNTRY

9.1. Asia-Pacific Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Inflammatory Bowel Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY COUNTRY

10.1. Latin America Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Inflammatory Bowel Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY COUNTRY

11.1. Middle East Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Inflammatory Bowel Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET BY COUNTRY

12.1. Africa Inflammatory Bowel Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Inflammatory Bowel Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Pfizer Inc.
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Johnson amp; Johnson Services Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. AbbVie Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Celltrion Healthcare Co., Ltd.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. CELGENE CORPORATION
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Takeda Pharmaceutical Company Limited
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Innovate Biopharmaceuticals
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. COSMO PHARMACEUTICALS
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Gilead Sciences
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

Request for Customization at https://www.acumenresearchandconsulting.com/request-customization/1505

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1505

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 16-Jul-2019